Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Company Overview

Chugai Pharmaceutical Co., Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer. The company also develops antibody-based medicines and other biologic treatments using proprietary technologies.

Chugai has a strategic alliance with Roche, which became its majority shareholder in 2002. Through this relationship, Chugai medicines are marketed in Japan and distributed internationally through Roche’s global network, while Chugai retains responsibility for its operations in Japan. The company is led by President and Chief Executive Officer Tatsuro Kosaka.

Key Stats

• Today's Range: $20.31 to $21.35
• 50-Day Range: $20.51 to $22.84
• 52-Week Range: $20.00 to $34.84
• Volume: 197,469 shs
• Average Volume: 238,930 shs
• Market Capitalization: $69.16 billion
• P/E Ratio: 22.84
• Dividend Yield: 1.14%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Chugai Pharmaceutical Stock Analysis - MarketRank™

Chugai Pharmaceutical scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Chugai Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Chugai Pharmaceutical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 28.13%

Earnings Growth

Earnings for Chugai Pharmaceutical are expected to grow by 28.13% in the coming year, from $0.96 to $1.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chugai Pharmaceutical is 22.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chugai Pharmaceutical is 22.79, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.21.

Price to Book Value per Share Ratio

Chugai Pharmaceutical has a P/B Ratio of 5.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Chugai Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chugai Pharmaceutical has recently increased by 90.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Chugai Pharmaceutical pays a meaningful dividend of 1.14%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Chugai Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Chugai Pharmaceutical is 26.09%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 19.51% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

Chugai Pharmaceutical has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Chugai Pharmaceutical this week, compared to 0 articles on an average week.

Search Interest

Only 4 people have searched for CHGCY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.01% of the stock of Chugai Pharmaceutical is held by institutions.

Company Calendar

• Last Earnings: 7/24/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 10/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CHGCY
• CIK: 1453934
• Web: www.chugai-pharm.co.jp
• Phone: (133) 281-6611
• Fax: N/A
• Employees: 7,872
• Year Founded: 1925

Profitability

• EPS (Trailing Twelve Months): $0.92
• Trailing P/E Ratio: 22.84
• Forward P/E Ratio: 21.89
• P/E Growth: N/A
• Net Income: $2.91 billion
• Net Margins: 35.09%
• Pretax Margin: 47.52%
• Return on Equity: 23.76%
• Return on Assets: 19.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.35
• Quick Ratio: 3.54

Sales & Book Value

• Annual Sales: $8.41 billion
• Price / Sales: 8.22
• Cash Flow: $0.92 per share
• Price / Cash Flow: 22.84
• Book Value: $4.12 per share
• Price / Book: 5.10

Miscellaneous

• Outstanding Shares: 3,291,427,000
• Free Float: N/A
• Market Cap: $69.16 billion
• Optionable: Not Optionable
• Beta: 0.59